Wiendl, Heinz

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet

Multiple Sclerosis Research StudiesSphingolipid Metabolism and Signaling

Cited by 942

Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria

Montalban, X., Lebrun-Frénay, C., Oh, J., Arrambide, G., Moccia, M., Pia Amato, M., Amezcua, L., Banwell, B., Bar-Or, A., Barkhof, F., et al. (2025) · The Lancet Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 551

How patients with multiple sclerosis acquire disability

Lublin, F. D., Häring, D. A., Ganjgahi, H., Ocampo, A., Hatami, F., Čuklina, J., Aarden, P., Dahlke, F., Arnold, D. L., Wiendl, H., et al. (2022) · Brain

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 549

Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro

Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 297

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Bril, V., Drużdż, A., Grosskreutz, J., Habib, A. A., Mantegazza, R., Sacconi, S., Utsugisawa, K., Vissing, J., Vu, T., Boehnlein, M., et al. (2023) · The Lancet Neurology

Myasthenia Gravis and ThymomaPeripheral Neuropathies and Disorders

Cited by 295

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Meier, S., Willemse, E. A. J., Schaedelin, S., Oechtering, J., Lorscheider, J., Melie-Garcia, L., Cagol, A., Barakovic, M., Galbusera, R., Subramaniam, S., et al. (2023) · JAMA Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 289

Bruton tyrosine kinase inhibitors for multiple sclerosis

Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 206

Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor+ Regulatory T Cells

Yogev, N., Frommer, F., Lukas, D., Kautz-Neu, K., Karram, K., Ielo, D., von Stebut, E., Probst, H.-C., van den Broek, M., Riethmacher, D., et al. (2012) · Immunity

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 197

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice

Bittner, S., Afzali, A. M., Wiendl, H., & Meuth, S. G. (2014) · Journal of Visualized Experiments

Multiple Sclerosis Research StudiesT-cell and B-cell Immunology

Cited by 171

Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease

Schröder, J. B., Pawlowski, M., Meyer zu Hörste, G., Gross, C. C., Wiendl, H., Meuth, S. G., Ruck, T., & Warnecke, T. (2018) · Frontiers in Neurology

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 134

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

DESGESCO (Dementia Genetics Spanish Consortium), E. (. D. E. D. B., van der Lee, S. J., biobank), E. (. D. E. D., IFGC (International FTD-Genomics Consortium), I. (. I. P. D. G. C., IPDGC (The International Parkinson Disease Genomics Consortium), Dementia), R.-F. (. A. M. F. I. F.-T., (NBB), N. B. B., The GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Conway, O. J., Jansen, I., et al. (2019) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 120

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

Abrahamyan, S., Eberspächer, B., Hoshi, M.-M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Schroeder, C., Grüter, T., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry

Multiple Sclerosis Research StudiesViral-associated cancers and disorders

Cited by 119

Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier

Gerwien, H., Hermann, S., Zhang, X., Korpos, E., Song, J., Kopka, K., Faust, A., Wenning, C., Gross, C. C., Honold, L., et al. (2016) · Science Translational Medicine

Multiple Sclerosis Research StudiesProtease and Inhibitor Mechanisms

Cited by 113

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G

Kailayangiri, S., Altvater, B., Spurny, C., Jamitzky, S., Schelhaas, S., Jacobs, A. H., Wiek, C., Roellecke, K., Hanenberg, H., Hartmann, W., et al. (2017) · OncoImmunology

Immune Cell Function and InteractionCAR-T cell therapy research

Cited by 104

Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease

Mykicki, N., Herrmann, A. M., Schwab, N., Deenen, R., Sparwasser, T., Limmer, A., Wachsmuth, L., Klotz, L., Köhrer, K., Faber, C., et al. (2016) · Science Translational Medicine

Multiple Sclerosis Research StudiesNeuroinflammation and Neurodegeneration Mechanisms

Cited by 60

Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort

Oertel, F. C., Krämer, J., Motamedi, S., Keihani, A., Zimmermann, H. G., Dimitriou, N. G., Condor-Montes, S., Bereuter, C., Cordano, C., Abdelhak, A., et al. (2023) · Neurology Neuroimmunology & Neuroinflammation

Multiple Sclerosis Research StudiesGlaucoma and retinal disorders

Cited by 33

Apraxia profiles-a single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer's disease

Johnen, A., Reul, S., Wiendl, H., Meuth, S. G., & Duning, T. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Dementia and Cognitive Impairment ResearchHistorical and Modern Theater Studies

Cited by 29

Deterministic programming of human pluripotent stem cells into microglia facilitates studying their role in health and disease.

Speicher, A. M., Korn, L., Csatári, J., Gonzalez-Cano, L., Heming, M., Thomas, C., Schroeter, C. B., Schafflick, D., Li, X., Gola, L., et al. (2022) · Proceedings of the National Academy of Sciences

Pluripotent Stem Cells ResearchNeuroinflammation and Neurodegeneration Mechanisms

Cited by 28

A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies

Rübsamen, N., Willemse, E. A. J., Leppert, D., Wiendl, H., Nauck, M., Karch, A., Kuhle, J., & Berger, K. (2022) · Frontiers in Neurology

Clinical Laboratory Practices and Quality ControlSkin and Cellular Biology Research

Cited by 27

Apraxia screening predicts Alzheimer pathology in frontotemporal dementia.

Pawlowski, M., Joksch, V., Wiendl, H., Meuth, S. G., Duning, T., & Johnen, A. (2019) · Journal of Neurology, Neurosurgery & Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 13